about
Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypesAntioxidant supplementation for lung disease in cystic fibrosisPseudomonas aeruginosa biofilms in cystic fibrosisPhysiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum.Reinforcement of the bactericidal effect of ciprofloxacin on Pseudomonas aeruginosa biofilm by hyperbaric oxygen treatment.Effect of long-term voluntary exercise wheel running on susceptibility to bacterial pulmonary infections in a mouse model.Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patientsNovel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosisThe clinical impact of bacterial biofilms.Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth.Molecular epidemiology of chronic Pseudomonas aeruginosa airway infections in cystic fibrosis.Development of antibiotic resistance and up-regulation of the antimutator gene pfpI in mutator Pseudomonas aeruginosa due to inactivation of two DNA oxidative repair genes (mutY, mutM).Evolutionary dynamics of bacteria in a human host environment.Pharmacokinetics/pharmacodynamics of colistin and imipenem on mucoid and nonmucoid Pseudomonas aeruginosa biofilms.Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patientsWithin-host microevolution of Pseudomonas aeruginosa in Italian cystic fibrosis patients.In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection.Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of CiprofloxacinOligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.A complex multilevel attack on Pseudomonas aeruginosa algT/U expression and algT/U activity results in the loss of alginate productionNovel experimental Pseudomonas aeruginosa lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis.Antibiotic resistance of bacterial biofilmsPhenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective.Respiratory bacterial infections in cystic fibrosis.Applying insights from biofilm biology to drug development - can a new approach be developed?Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.Genome Sequence of Pseudomonas aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate.Proteome-wide antigen discovery of novel protective vaccine candidates against Staphylococcus aureus infection.Detection of NDM-2-producing Acinetobacter baumannii and VIM-producing Pseudomonas aeruginosa in Palestine.Antibiotic treatment of biofilm infections.Diagnosis of biofilm infections in cystic fibrosis patients.Constitutive high expression of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampDCellular responses of A549 alveolar epithelial cells to serially collected Pseudomonas aeruginosa from cystic fibrosis patients at different stages of pulmonary infection.Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection.Hyperbaric oxygen sensitizes anoxic Pseudomonas aeruginosa biofilm to ciprofloxacin.Immunisation in the current management of cystic fibrosis patients.Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
P50
Q21132701-DFC1BE8A-6488-4A15-BA1A-41F9E906C9D6Q24194437-5179F5DD-3C70-4AA9-AB32-CCE2D0DBBF46Q28299966-3CA633B6-4A62-4429-96D9-9A0092FC1677Q30868724-EA1BCFE2-EE4A-4612-8CFE-2E1777618025Q31037210-523672F9-0565-4055-BCE1-80A981722D11Q31146786-8DB39F7E-9C3E-4877-9480-829C1FBF680CQ33559774-4D8C7A5C-4F8C-4F13-BA8F-FD49F51109EEQ33769205-99997E82-44AA-45F0-A1D9-8B17756D9955Q33870211-7C9AC755-A041-43D9-B18B-15A74890842EQ34167016-94BD3D12-26BE-49C9-85EA-786DF8788FB6Q34500683-7D072481-4A13-47BF-AA67-095430140204Q34633745-26EEF00E-7FFB-4EEB-9FA9-4E6502E37F14Q34937408-93FC7A80-7FD5-4161-9587-CA03A0C5957CQ35191390-8E6A0148-D6E4-4F73-BBA4-3753341B3C93Q35614230-0A8BB623-84C6-4CB2-ABB4-12119AB7552EQ35784162-C5BBC7AE-D580-4C5D-A25E-88C62B33CE2CQ35813781-A8A9EB5F-48C6-4885-8E60-27201C46F69EQ35941284-EBC0976C-3FDC-4575-A468-7C9374A61DDFQ36228925-88AF4DF3-C38C-4C32-A685-4AFD2D83D9ECQ36887970-16674F5C-341B-4C7A-AD16-2B933FB3645EQ37119379-DC2DDAEC-3E59-4EDE-B4EB-D4D3A22F5F4CQ37142642-C3EFAF40-79CB-436F-B201-866A23F29050Q37413900-670D3018-4434-4DEA-B824-D659BC84B2CCQ37690946-F8F71C7E-ED9E-46E2-8DD8-ECF0F4804962Q38006032-385950F5-F279-401F-836A-60A2855C8CB3Q38059441-CE100A84-7A30-4446-B3AF-EFFB6C06984BQ38085510-06F07F3A-9F9C-4FDB-9D7B-B9175AD1773EQ38147863-6A864E96-2B16-4F53-B406-138C710BC3A4Q38283496-2840BD04-0DBE-4834-A6CD-353A808599A1Q38636624-90BE3591-5291-483D-B55C-3A34556066A5Q38833957-83FBD2C9-DA31-4BCE-B494-4BDC6A0E964EQ39165224-243053D9-2FEE-4F5E-A11B-FF71297D9AB2Q39240734-C82D82B3-A7D3-4D31-859A-34BE33D2DC81Q39240814-9C1CDF6E-D7CC-4925-8B16-FC191CA4E821Q39657855-F9F42D0B-A57B-4331-AED6-CE2344498BA4Q39696154-52F71012-7780-4FE9-BEE9-C2E094BB304EQ39997040-51F14A96-C25F-4C94-86F3-F988DA4F256DQ40065973-75FEC09E-D914-4FE7-8576-C79C110A050BQ40410972-BC941AF2-DFD3-4605-9A4F-ABD63A612C68Q40533096-79BA8B28-C5A5-4383-BD9D-71A15E7842B5
P50
description
dansk-rumænsk læge og forsker
@da
researcher ORCID ID = 0000-0001-5648-4858
@en
wetenschapper
@nl
name
Oana Ciofu
@ast
Oana Ciofu
@da
Oana Ciofu
@de
Oana Ciofu
@en
Oana Ciofu
@es
Oana Ciofu
@fo
Oana Ciofu
@fr
Oana Ciofu
@is
Oana Ciofu
@kl
Oana Ciofu
@nb
type
label
Oana Ciofu
@ast
Oana Ciofu
@da
Oana Ciofu
@de
Oana Ciofu
@en
Oana Ciofu
@es
Oana Ciofu
@fo
Oana Ciofu
@fr
Oana Ciofu
@is
Oana Ciofu
@kl
Oana Ciofu
@nb
prefLabel
Oana Ciofu
@ast
Oana Ciofu
@da
Oana Ciofu
@de
Oana Ciofu
@en
Oana Ciofu
@es
Oana Ciofu
@fo
Oana Ciofu
@fr
Oana Ciofu
@is
Oana Ciofu
@kl
Oana Ciofu
@nb
P106
P1153
6603713801
P2038
Oana_Ciofu
P21
P31
P496
0000-0001-5648-4858
P6634
oana-ciofu-5ab92125